Article
Cardiac & Cardiovascular Systems
Bertram Pitt, Deepak L. Bhatt, Michael Szarek, Christopher P. Cannon, Lawrence A. Leiter, Darren K. Mcguire, Julia B. Lewis, Matthew C. Riddle, Adriaan A. Voors, Marco Metra, Lars H. Lund, Michel Komajda, Jeffrey M. Testani, Christopher S. Wilcox, Piotr Ponikowski, Renato D. Lopes, Justin A. Ezekowitz, Franklin Sun, Michael J. Davies, Subodh Verma, Mikhail N. Kosiborod, SOLOIST WHF Investigators
Summary: The study finds that starting sotagliflozin before discharge in type 2 diabetes patients hospitalized for WHF can significantly decrease cardiovascular deaths and HF events through 30 and 90 days after discharge. However, sotagliflozin may have slightly higher rates of diarrhea and volume-related events compared to placebo.
JACC-HEART FAILURE
(2023)
Article
Endocrinology & Metabolism
Feifei Zhou, Nannan Du, Lulin Zhou, Chenxi Wang, He Ren, Qiang Sun
Summary: This meta-analysis demonstrates that sotagliflozin has an acceptable safety profile in patients with diabetes, with adverse events including genital mycotic infection, related-to-acidosis events, diarrhea, volume depletion, and severe nocturnal hypoglycemia events. The subgroup analysis of sotagliflozin dosage is of great clinical significance for guiding the use of sotagliflozin in patients with diabetes in the future.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Pharmacology & Pharmacy
Allissa Long, Marissa Salvo
Summary: This study provides a comprehensive review of the pharmacology, clinical efficacy, and safety evidence of sotagliflozin, the first dual inhibitor of SGLT1 and SGLT2. It compares the findings with existing SGLT2 inhibitors and highlights the need for more research to determine the benefits of sotagliflozin.
ANNALS OF PHARMACOTHERAPY
(2023)
Article
Endocrinology & Metabolism
Siti Sanaa Wan Azman, Norlela Sukor, Muhammad Yusuf Abu Shamsi, Ilham Ismail, Nor Azmi Kamaruddin
Summary: The use of SGLT2 inhibitors has led to an increase in cases of EDKA, which is difficult to treat using conventional methods. This case report demonstrates a paradigm shift in the management of SGLT2 inhibitor-induced EDKA by successfully correcting the condition using high-calorie glucose infusion and tight glycemic control.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Ghadeer K. Dawwas, James H. Flory, Sean Hennessy, Charles E. Leonard, James D. Lewis
Summary: In this comparative safety study using real-world data, newly prescribed SGLT2 inhibitors were associated with a higher rate of diabetic ketoacidosis in patients with type 2 diabetes compared to DPP-4 inhibitors and sulfonylureas. Clinicians should be aware of this association.
Article
Endocrinology & Metabolism
Ghadeer K. Dawwas, James H. Flory, Sean Hennessy, Charles E. Leonard, James D. Lewis
Summary: This study examined the association of SGLT2 inhibitors with diabetic ketoacidosis in patients with type 2 diabetes compared to DPP-4 inhibitors and sulfonylureas. The results showed that patients newly prescribed SGLT2 inhibitors had a higher rate of diabetic ketoacidosis compared to the other two drug classes. Clinicians should be cautious about this association when prescribing SGLT2 inhibitors.
Article
Medicine, General & Internal
Deepak L. Bhatt, Michael Szarek, Bertram Pitt, Christopher P. Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia B. Lewis, Matthew C. Riddle, Silvio E. Inzucchi, Mikhail N. Kosiborod, David Z. I. Cherney, Jamie P. Dwyer, Benjamin M. Scirica, Clifford J. Bailey, Rafael Diaz, Kausik K. Ray, Jacob A. Udell, Renato D. Lopes, Pablo Lapuerta, P. Gabriel Steg
Summary: The trial involving 10,584 patients with diabetes and chronic kidney disease showed that sotagliflozin resulted in fewer deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure compared to placebo. However, there were adverse events such as diarrhea, mycotic infections, and diabetic ketoacidosis associated with sotagliflozin.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Deepak L. Bhatt, Michael Szarek, P. Gabriel Steg, Christopher P. Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia B. Lewis, Matthew C. Riddle, Adriaan A. Voors, Marco Metra, Lars H. Lund, Michel Komajda, Jeffrey M. Testani, Christopher S. Wilcox, Piotr Ponikowski, Renato D. Lopes, Subodh Verma, Pablo Lapuerta, Bertram Pitt
Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Sarah L. Armour, Alexander Frueh, Jakob G. Knudsen
Summary: Diabetes is characterized by high blood sugar levels due to insulin resistance and compromised insulin release. Alpha cells in the pancreas also have dysregulation of glucagon secretion. SGLT2 inhibitors, while effective in reducing blood sugar levels, also increase glucagon concentrations. Recent studies have shown that SGLTs are involved in the regulation of glucagon secretion, with SGLT1 playing a central role in alpha cell function.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Maximilian G. Posch, Niklas Walther, Ele Ferrannini, David R. Powell, Phillip Banks, Suman Wason, Raphael Dahmen
Summary: This study compared the effects of selective SGLT2 inhibition and dual inhibition of SGLT1 and SGLT2. The results showed that both treatments had similar impacts on glycemic control, blood pressure control, and cardiovascular biomarkers. However, only the dual inhibitor of SGLT1 and SGLT2 was able to inhibit intestinal SGLT1 after breakfast, leading to larger changes in incretin responses.
Article
Cardiac & Cardiovascular Systems
Huan Chen, Yochai Birnbaum, Regina Ye, Hsiu-Chiung Yang, Mandeep Bajaj, Yumei Ye
Summary: SGLT2 inhibitors increase plasma ketone concentrations and may induce ketoacidosis in diabetes patients. Dehydration can precipitate SGLT2 inhibitor-induced ketoacidosis in type-2 diabetes. Dapagliflozin attenuated the development of ketoacidosis and associated signaling pathways in T1DM mice.
CARDIOVASCULAR DRUGS AND THERAPY
(2022)
Article
Medicine, General & Internal
Rabia Khalid Alduraibi, Yazeed Mohammed Alrebdi, Yosef Fahad Altowayan
Summary: This case report highlights the rare occurrence of euglycemic diabetic ketoacidosis (EDKA) when blood glucose levels are <250 mg/dL, and implicates glucagon-like peptide 1 (GLP1) receptor agonists and sodium-glucose co-transporter 2 inhibitors as potential triggers. The report emphasizes the importance of using diabetes medications in a stepwise manner and advising patients not to excessively restrict their carbohydrate intake while being treated with GLP1 receptor agonists to prevent EDKA.
Article
Biochemistry & Molecular Biology
Afif Nakhleh, Areen Othman, Amin Masri, Moshe Zloczower, Sagit Zolotov, Naim Shehadeh
Summary: This study compared the clinical course and outcomes of DKA in T2DM patients who received treatment with SGLT2 inhibitors versus those who did not. The results showed that T2DM patients with DKA who received SGLT2 inhibitors had lower long-term mortality from any cause.
Article
Cardiac & Cardiovascular Systems
Luka Cavka, Urska Bencak Ferko, Natasa Pitz, Zoranco Trpkovski, Mitja Lainscak
Summary: This article presents a case of euDKA in an HFpEF patient treated with SGLT2i, which recovered completely after appropriate treatment without any sequelae. This case is significant for ongoing SGLT2i trials in HFpEF and in clinical practice.
Review
Pharmacology & Pharmacy
Aqsa Ashfaq, Myriam Meineck, Andrea Pautz, Ebru Arioglu-Inan, Julia Weinmann-Menke, Martin C. Michel
Summary: A systematic review of studies on SGLT2 inhibitors in rodent models of diabetes showed that these inhibitors not only improved glycemic control but also had various beneficial effects on renal function. These nephroprotective effects were observed in different animal models of type 1 and type 2 diabetes/obesity. SGLT2 inhibitors had positive effects on lipid metabolism, blood pressure, glomerulosclerosis, renal tubular fibrosis, apoptosis, oxidative stress, and inflammation, which are important pathomechanisms for atherosclerosis and renal health. However, more data on female animals and direct comparative studies with other anti-diabetic compounds are needed.
PHARMACOLOGY & THERAPEUTICS
(2023)